AR063529A1 - Compuestos de pirazolina - Google Patents
Compuestos de pirazolinaInfo
- Publication number
- AR063529A1 AR063529A1 ARP070104787A ARP070104787A AR063529A1 AR 063529 A1 AR063529 A1 AR 063529A1 AR P070104787 A ARP070104787 A AR P070104787A AR P070104787 A ARP070104787 A AR P070104787A AR 063529 A1 AR063529 A1 AR 063529A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen
- substituents
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicacion 1: Un compuesto, o una sal farmacéuticamente aceptable del compuesto, en el que el compuesto tiene la estructura de Formula (1) en la que; X se selecciona entre el grupo constituido por -CH2- y -O-; R1 se selecciona entre el grupo constituido por alquilo, cicloalquilo, cicloalquenilo, fenilo, y heterociclilo, donde el sustituyente heterociclilo es un anillo heterociclilo de cinco o seis miembros que comprende al menos un heteroátomo en el anillo seleccionado entre oxígeno, azufre y nitrogeno; y donde los sustituyentes alquilo, cicloalquilo, cicloalquenilo, fenilo y heterociclilo pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados independientemente entre el grupo constituido por hidroxi, halogeno, alquilo y haloalquilo; R2 se selecciona entre el grupo constituido por hidrogeno y alquilo; R3A y R3B se seleccionan independientemente entre el grupo constituido por hidrogeno y alquilo; R4, R6 y R7 se seleccionan independientemente entre el grupo constituido por hidrogeno, halogeno, hidroxi, alquilo, haloalquilo, hidroxialquilo y alcoxi; R5 se selecciona entre el grupo constituido por hidrogeno, -(CH2)mOR50, -(CH2)mC(O)R50, -(CH2)mC(O)OR50, -(CH2)mC(O)NR51R52, -(CH2)mNR51R52, - (CH2)mN(R51)C(O)R52 y -(CH2)mS(O)nR50; m es 0, 1, 2, 3, 4, 5 o 6, n es 0, 1 o 2; R50 se selecciona entre el grupo constituido por hidrogeno y alquilo; R51 y R52 se seleccionan independientemente entre el grupo constituido por hidrogeno y alquilo; o R51 yR52 junto con el nitrogeno al que están unidos forman un anillo heterociclilo de cinco o seis miembros; donde los sustituyentes alquilo R50, R51 y R52 y el sustituyente heterociclilo R51/R52 pueden estar independiente y opcionalmente sustituidos con uno o más sustituyentes seleccionados entre el grupo constituido por halogeno, pirolidinilo, -OR53, -C(O)R53, -C(O)OR53, -C(O)NR54R55, -NR54R55, -N(R56)C(O)R53; - S(O)pR53 y -S(O)pNR54R55, p es 0, 1 o 2; R53 se selecciona entre el grupo constituido por hidrogeno, alquilo, haloalquilo, hidroxialquilo y carboxialquilo; R54 y R55 se seleccionan independientemente entre el grupo constituido por hidrogeno, alquilo, haloalquilo, hidroxialquilo y carboxialquilo; o R54 y R55junto con el nitrogeno al que están unidos forman un anillo heterociclilo decinco o seis miembros; R56se selecciona entre el grupo constituido por hidrogeno y alquilo; y R8 se selecciona entre el grupo constituido por fenilo, piridinilo y pirimidinilo; donde los sustituyentes fenilo, piridinilo y pirimidinilo pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados independientemente entre el grupo constituido por halogeno, ciano, hidroxi, carboxi, alquilo, haloalquilo, cianoalquilo, hidroxialquilo, carboxialquilo, alcoxi, haloalcoxi,cianoalcoxi, amino, alquilamino, dialquilamino y alcoxicarbonilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86360606P | 2006-10-31 | 2006-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063529A1 true AR063529A1 (es) | 2009-01-28 |
Family
ID=39027523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104787A AR063529A1 (es) | 2006-10-31 | 2007-10-29 | Compuestos de pirazolina |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US7781428B2 (es) |
| EP (1) | EP2089367B1 (es) |
| JP (1) | JP4977760B2 (es) |
| KR (1) | KR101107800B1 (es) |
| CN (1) | CN101541757A (es) |
| AP (1) | AP2527A (es) |
| AR (1) | AR063529A1 (es) |
| AT (1) | ATE537151T1 (es) |
| AU (1) | AU2007315884B2 (es) |
| BR (1) | BRPI0717937A2 (es) |
| CA (1) | CA2667966C (es) |
| CL (1) | CL2007003154A1 (es) |
| CO (1) | CO6160307A2 (es) |
| CR (1) | CR10725A (es) |
| CU (1) | CU23779B7 (es) |
| CY (1) | CY1112311T1 (es) |
| DK (1) | DK2089367T3 (es) |
| EA (1) | EA016370B1 (es) |
| ES (1) | ES2375877T3 (es) |
| GE (1) | GEP20115239B (es) |
| GT (1) | GT200700096A (es) |
| HN (1) | HN2007000437A (es) |
| HR (1) | HRP20120078T1 (es) |
| IL (1) | IL198241A0 (es) |
| MA (1) | MA30821B1 (es) |
| MX (1) | MX2009004662A (es) |
| MY (1) | MY145795A (es) |
| NI (1) | NI200900071A (es) |
| NO (1) | NO20091741L (es) |
| NZ (1) | NZ575923A (es) |
| PE (1) | PE20081472A1 (es) |
| PL (1) | PL2089367T3 (es) |
| PT (1) | PT2089367E (es) |
| RS (2) | RS20090208A (es) |
| SI (1) | SI2089367T1 (es) |
| TN (1) | TN2009000160A1 (es) |
| TW (1) | TWI357327B (es) |
| UA (1) | UA92670C2 (es) |
| UY (1) | UY30670A1 (es) |
| WO (1) | WO2008053300A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| EP2597089A1 (en) * | 2009-10-29 | 2013-05-29 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| US8957052B2 (en) | 2010-05-10 | 2015-02-17 | Universite Paris Descartes | Methods and compositions for the treatment of fluid accumulation in and/or under the retina |
| WO2011141848A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
| WO2011157798A1 (en) | 2010-06-16 | 2011-12-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for stimulating reepithelialisation during wound healing |
| CN102372710A (zh) * | 2010-08-18 | 2012-03-14 | 山东轩竹医药科技有限公司 | 作为盐皮质激素受体拮抗剂的并环类化合物 |
| WO2012048022A2 (en) * | 2010-10-05 | 2012-04-12 | Nova Southeastern University | Methods and compositions for therapeutic modulation of aldosterone levels in heart disease |
| CN106536491B (zh) | 2014-06-30 | 2018-12-18 | 阿斯利康(瑞典)有限公司 | 作为盐皮质激素受体调节剂的苯并噁嗪酮酰胺 |
| US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| US20190262363A1 (en) | 2016-07-26 | 2019-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| WO2018045149A1 (en) | 2016-09-02 | 2018-03-08 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
| CN109051490B (zh) | 2018-09-18 | 2024-07-23 | 深圳市鲸仓科技有限公司 | 可移动式密集存拣装置 |
| US20230151425A1 (en) | 2020-03-11 | 2023-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| EP4395785A1 (en) | 2021-08-31 | 2024-07-10 | Inserm (Institut National de la Santé et de la Recherche Scientifique) | Methods for the treatment of ocular rosacea |
| CN113679716B (zh) | 2021-10-13 | 2024-03-26 | 史大永 | 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 |
| CN114230457B (zh) * | 2022-01-04 | 2023-06-09 | 中山大学 | 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1086068A (en) * | 1964-09-02 | 1967-10-04 | Ici Ltd | Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein |
| BE789948A (fr) * | 1971-10-13 | 1973-04-11 | Sandoz Sa | Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments |
| US3816438A (en) * | 1972-12-22 | 1974-06-11 | Sandoz Ag | 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles |
| US3843666A (en) * | 1973-05-29 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
| US4866025A (en) * | 1988-09-30 | 1989-09-12 | Eastman Kodak Company | Thermally-transferable fluorescent diphenylpyrazolines |
| EP0623122B1 (en) * | 1992-01-23 | 1997-03-05 | Pfizer Inc. | Benzopyran and related LTB4-antagonists. |
| GB9318691D0 (en) | 1993-09-09 | 1993-10-27 | Merck Sharp & Dohme | Therapeutic agents |
| ID16283A (id) | 1996-03-20 | 1997-09-18 | Astra Pharma Prod | Senyawa yang berguna dibidang farmasi |
| JP2001501180A (ja) * | 1996-09-05 | 2001-01-30 | アストラ・フアーマシユウテイカルズ・リミテツド | 新規なアリールピリダジン |
| JPH10273467A (ja) * | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
| IT1292092B1 (it) | 1997-06-05 | 1999-01-25 | Geange Ltd | Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali |
| CN1311678A (zh) | 1998-04-30 | 2001-09-05 | 巴斯福股份公司 | 具有蛋白激酶活性的取代的三环吡唑衍生物 |
| US6432974B1 (en) * | 2000-02-04 | 2002-08-13 | Wyeth | Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor |
| ATE448207T1 (de) | 2002-03-08 | 2009-11-15 | Merck & Co Inc | Mitotische kinesin-hemmer |
| AU2003230581A1 (en) | 2002-03-15 | 2003-09-29 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| ATE339419T1 (de) | 2002-08-02 | 2006-10-15 | Vertex Pharma | Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren |
| JP4519657B2 (ja) | 2002-09-18 | 2010-08-04 | ファイザー・プロダクツ・インク | 形質転換成長因子（ｔｇｆ）阻害剤としての新規なピラゾ−ル化合物 |
| EP1597254A1 (en) | 2003-01-22 | 2005-11-23 | Eli Lilly and Company | Indole-derivative modulators of steroid hormone nuclear receptors |
| CN1918151A (zh) | 2003-12-19 | 2007-02-21 | 伊莱利利公司 | 三环甾类激素核受体调节剂 |
| JP2007230869A (ja) | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | アルドステロン受容体拮抗剤 |
| WO2006010142A2 (en) | 2004-07-14 | 2006-01-26 | Ligand Pharmaceuticals, Inc. | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use |
| HUE041596T2 (hu) | 2004-07-30 | 2019-05-28 | Exelixis Inc | Pirrol származékok mint gyógyászati szerek |
| EP1844020B1 (en) | 2005-01-10 | 2017-09-06 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptor ligands |
| JPWO2006077821A1 (ja) | 2005-01-19 | 2008-06-19 | 大日本住友製薬株式会社 | アルドステロン受容体調節剤としての芳香族スルホン化合物 |
| CA2594662A1 (en) | 2005-02-10 | 2006-08-17 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
-
2007
- 2007-10-17 ES ES07825488T patent/ES2375877T3/es active Active
- 2007-10-17 JP JP2009533977A patent/JP4977760B2/ja not_active Expired - Fee Related
- 2007-10-17 KR KR1020097008836A patent/KR101107800B1/ko not_active IP Right Cessation
- 2007-10-17 EA EA200970341A patent/EA016370B1/ru not_active IP Right Cessation
- 2007-10-17 AP AP2009004822A patent/AP2527A/xx active
- 2007-10-17 UA UAA200903302A patent/UA92670C2/ru unknown
- 2007-10-17 DK DK07825488.5T patent/DK2089367T3/da active
- 2007-10-17 RS RSP-2009/0208A patent/RS20090208A/sr unknown
- 2007-10-17 NZ NZ575923A patent/NZ575923A/en not_active IP Right Cessation
- 2007-10-17 CN CNA2007800433330A patent/CN101541757A/zh active Pending
- 2007-10-17 BR BRPI0717937-5A2A patent/BRPI0717937A2/pt not_active IP Right Cessation
- 2007-10-17 MY MYPI20091613A patent/MY145795A/en unknown
- 2007-10-17 PT PT07825488T patent/PT2089367E/pt unknown
- 2007-10-17 CA CA2667966A patent/CA2667966C/en not_active Expired - Fee Related
- 2007-10-17 GE GEAP200711240A patent/GEP20115239B/en unknown
- 2007-10-17 SI SI200730830T patent/SI2089367T1/sl unknown
- 2007-10-17 AU AU2007315884A patent/AU2007315884B2/en not_active Ceased
- 2007-10-17 PL PL07825488T patent/PL2089367T3/pl unknown
- 2007-10-17 EP EP07825488A patent/EP2089367B1/en active Active
- 2007-10-17 RS RS20120051A patent/RS52203B/en unknown
- 2007-10-17 WO PCT/IB2007/003207 patent/WO2008053300A1/en active Application Filing
- 2007-10-17 MX MX2009004662A patent/MX2009004662A/es active IP Right Grant
- 2007-10-17 AT AT07825488T patent/ATE537151T1/de active
- 2007-10-24 US US11/923,248 patent/US7781428B2/en not_active Expired - Fee Related
- 2007-10-29 UY UY30670A patent/UY30670A1/es not_active Application Discontinuation
- 2007-10-29 AR ARP070104787A patent/AR063529A1/es not_active Application Discontinuation
- 2007-10-30 GT GT200700096A patent/GT200700096A/es unknown
- 2007-10-30 TW TW096140838A patent/TWI357327B/zh not_active IP Right Cessation
- 2007-10-30 PE PE2007001482A patent/PE20081472A1/es not_active Application Discontinuation
- 2007-10-31 CL CL200703154A patent/CL2007003154A1/es unknown
- 2007-10-31 HN HN2007000437A patent/HN2007000437A/es unknown
-
2009
- 2009-04-17 CU CU20090058A patent/CU23779B7/es not_active IP Right Cessation
- 2009-04-17 CR CR10725A patent/CR10725A/es not_active Application Discontinuation
- 2009-04-20 IL IL198241A patent/IL198241A0/en unknown
- 2009-04-21 CO CO09040130A patent/CO6160307A2/es unknown
- 2009-04-24 TN TNP2009000160A patent/TN2009000160A1/fr unknown
- 2009-04-29 NI NI200900071A patent/NI200900071A/es unknown
- 2009-04-30 MA MA31831A patent/MA30821B1/fr unknown
- 2009-05-04 NO NO20091741A patent/NO20091741L/no not_active Application Discontinuation
-
2010
- 2010-07-12 US US12/834,117 patent/US20100280016A1/en not_active Abandoned
-
2011
- 2011-10-20 US US13/277,270 patent/US20120035131A1/en not_active Abandoned
-
2012
- 2012-01-23 HR HR20120078T patent/HRP20120078T1/hr unknown
- 2012-01-23 CY CY20121100076T patent/CY1112311T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063529A1 (es) | Compuestos de pirazolina | |
| PE20210040A1 (es) | Moduladores de la via de estres integrada | |
| AR059494A1 (es) | Derivados biciclicos de bisamida con actividad pesticida | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| CO6220952A2 (es) | Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida | |
| ES2567311T3 (es) | 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP | |
| CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| AR060875A1 (es) | Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana | |
| NO20075768L (no) | Hydroksybenzamidderivater og deres anvendelse som inhibitorer av HSP90 | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR052863A1 (es) | Compuestos de quinolina heteroaromaticos | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| AR095706A1 (es) | Indazoles sustituidos con heteroarilo | |
| CO6140058A2 (es) | Derivados de 2-pirazinona para el tratamiento de la enfermedad o condicion en la cual es benefica la inhibición de la actividad elastasa de neutrofilos | |
| AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
| AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| CO6190554A2 (es) | Compuestos de 4-hidroxi-2-oxo-2, 3-dihidro-1, 3-benzotiazol-7il para la modulacion de la actividad del adrenoreceptor beta2 | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| CO6260077A2 (es) | Pirimidinas biciclicas fusionadas | |
| RS52562B (en) | (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |